PCA
AGN

Providence Capital Advisors’s Allergan plc AGN Stock Holding History

Providence Capital Advisors’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-62
Closed -$12K – 334
2019
Q4 		$12K Buy
+62
New +$11.2K 0.01% 172
2019
Q1 		– Hold
0
– – – 229

Other funds holding AGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Providence Capital Advisors's AGN Position: Q1 2020 in Review

Providence Capital Advisors sold out of Allergan plc (AGN) in Q1 2020, closing a stake of 62 shares — an estimated $12K sold.

Providence Capital Advisors first reported a position in AGN in Q4 2019 and held it in 1 quarter. The position peaked at $12K in Q4 2019. 876 funds tracked by Wall St. Rank hold AGN as of Q1 2020.

  • Providence Capital Advisors reported no remaining Allergan plc position as of Q1 2020 after selling out during the quarter.
  • Providence Capital Advisors sold 62 Allergan plc shares in Q1 2020, an estimated $12K.
  • Providence Capital Advisors first reported a position in Allergan plc in Q4 2019 and held it in 1 quarter.
  • Providence Capital Advisors's Allergan plc position peaked at $12K in Q4 2019.
  • 876 funds tracked by Wall St. Rank held Allergan plc as of Q1 2020.

Based on Providence Capital Advisors's 13F filing for Q1 2020, filed 12 May 2020.